Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.82 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.56 |
| ▸ | CDK2 | P24941 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840934 | 1.00 | CDK1 (0.82) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL7203055 | 0.91 | CDK1 (0.82) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5839316 | 0.91 | CDK1 (0.82) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5839320 | 0.91 | CDK1 (0.82) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5840414 | 0.91 | CDK1 (0.83) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5840409 | 0.91 | CDK1 (0.83) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5840330 | 0.90 | CDK1 (1.00) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5840337 | 0.90 | CDK1 (1.00) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5840468 | 0.89 | CDK1 (0.84) | CDK1SRCPRKCAPDGFRACCNE1 | |
| SCHEMBL5840463 | 0.89 | CDK1 (0.84) | CDK1SRCPRKCAPDGFRACCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | claimed |
| US-20240224960-A1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | PESTELL RICHARD G (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240224960-A1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | PESTELL RICHARD G (US) | 2024-07-11 | — | — | US | disclosed |
| US-10952415-B2 | Prostate cancer cell lines, gene signatures and uses thereof | Pestell, Richard G. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20130040972-A1 | USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | MANLEY PAUL W (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130040972-A1 | USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | MANLEY PAUL W (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20100152198-A1 | USE OF C-SRC INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152198-A1 | USE OF C-SRC INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| WO-2007116025-A2 | USE OF C-SRC INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-7091346-B1 | Purine derivatives and processes for their preparation | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952415-B2 | Prostate cancer cell lines, gene signatures and uses thereof | MYC, MYCBP, CD44 | CDK1 1213/4885SRC 9/4885PRKCA 2536/4885 |
| US-20240224960-A1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | MYC, MYCBP, CD44 | CDK1 1394/4885SRC 11/4885PRKCA 2607/4885 |
| US-20130040972-A1 | USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | BTK, SRC, TEC | CDK1 373/4885SRC 2/4885PRKCA 172/4885 |
| US-20100152198-A1 | USE OF C-SRC INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | BTK, SRC, TEC | CDK1 373/4885SRC 2/4885PRKCA 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.